3BOOGAERTS MA,MAERTENS.J,Van DerGeest R,et al.Phamacokine tics and safety of a 7-day adminstation of intravenous itvaconazole followed by a 14-day adminstration of itraconazole oral solution in patients with hematilogic malignancy[J].Antimicrob Agents Chemother,2001,45 (3):981-985.
4JOHNSON LB,KAUFFMAN CA.Voriconazole:a new triazole antifungal agent[J].Clin Infect Dis,2003,36(5):630-637.
5ABRUZZO GK,FLATTERY AM,GILL CJ,et al.Evaluation of the ciesechinocandin antifungal MK-0991 (L-743,872):efficacies inmouse models of disseminated aspergillosis,candidiasis,and cryptococcosis[J].Antimicrob Agents Chemother,1997,41 (11):2333-2338.
6PACETTI SA,GELONE SP.Caspofungin acetate for treat ment of invasive fungalinfections[J].Ann Pharmacother,2003,37 (1):90-98.
10TAWARA S, IKEDA F, MAKI K, et al. In vitro activities of a new lipopeptide antifungal agent micafungin against a variety of clinically important fungi[ J]. Antimicrob Agents Chemother, 2000,44 (1) :57 -62.
